Their structures were established by analysis of spectroscopic data. Compounds 1-8 were evaluated for cytotoxic activities against human cancer cell lines A549, HL-60, HCT116 and ZR-75-30. Compounds 1, 2, 3, 6 and 7 showed modest cytotoxicity against HL-60, HCT116 and ZR-75-30. (C) 2012 Phytochemical Society BIIB057 of Europe. Published by Elsevier B. V. All rights reserved.”
“OBJECTIVE: To establish whether alterations of brain structures in Alzheimer’s disease are associated with executive dysfunction. METHODS: Nineteen patients with Alzheimer’s disease and 22 older control subjects underwent a comprehensive evaluation. The clock drawing
test, digit span test, executive motor function test, Behavioral Assessment of the Dysexecutive Syndrome battery (Rule Shift Cards test), and Stroop test were used to evaluate executive dysfunction. Oligomycin A A multiparametric approach using the FreeSurfer image analysis suite provided a description of volumetric and geometric features of the gray matter structures.
RESULTS: The cortical thickness maps showed a negative correlation between the Behavioral Assessment of the Dysexecutive Syndrome battery (Rule Shift Cards test) and the right middle frontal gyrus; a positive correlation between the executive motor function test and the left superior parietal gyrus, left middle temporal
gyrus, bilateral supramarginal gyri, right middle frontal gyrus, and right precuneus; a negative correlation between the Stroop test (part III) and the right superior parietal gyrus; and a negative correlation between the Stroop test (part III) and the right middle temporal gyrus.
CONCLUSION: Executive dysfunction in Alzheimer’s disease is correlated with alterations not only in the frontal areas but also within many temporal selleck products and parietal regions.”
“Purpose of review
Leflunomide has been used off-label in renal transplantation because of the attractive combination of antiviral and immunosuppressive effects. This study intends to review the clinical applications
of leflunomide with interest to transplantation.
In renal transplantation, particularly in BK nephropathy, the use of leflunomide has attempted to model the in-vitro antiviral experimental data, leading to the use of higher dosages than those studied in the approved use in rheumatoid arthritis. Concerns of toxicity with this approach have been raised, and a newer association with hemolysis and thrombotic microangiopathy has been reported. By attempting to target levels, the use of leflunomide in transplantation has been difficult because of the long half-life of the drug and the high interpatient variability. Higher leflunomide levels may lead to disproportionate immunosuppressive effects and decrease the antiviral properties. Newer data suggest that the correlation between leflunomide levels and BK nephropathy outcome is unclear.